Sanofi
Study supports GLP-1 agonists for weight loss
January 10, 2012Research and Development, Sales and Marketing GLP-1, Novo Nordisk, Sanofi, diabetes, lilly
An independent study by academics has concluded that GLP-1 agonist drugs help patients to lose weight – with the effect …
Sanofi sheds dermatology unit for $423 million
December 19, 2011Manufacturing and Production, Sales and Marketing Canada, Dermik, Sanofi
Sanofi has completed the sale of its Canadian-based dermatology business Dermik for $422.5 million. The unit has been sold to …
No cancer link with Lantus, says Sanofi
December 7, 2011Sales and Marketing Cancer, Lantus, Sanofi, diabetes, insulin, safety
Sanofi has presented a new meta-analysis which suggests its insulin blockbuster Lantus does not raise the risk of cancer. A …
UK government drops Cervarix for Gardasil
November 28, 2011Sales and Marketing Cervarix, GSK, Gardasil, MSD, Sanofi
The UK government has performed a U-turn on its HPV vaccine programme by favouring Sanofi and MSD’s Gardasil over GlaxoSmithKline’s …
Multaq raises risk of death in permanent AF patients
November 16, 2011Sales and Marketing AF, Multaq, Sanofi
More bad news for Sanofi’s Multaq as new data shows the drug doubles the risk of death in people with …
Sanofi’s Lemtrada beats Rebif in new study
November 14, 2011Research and Development, Sales and Marketing Lemtrada, Rebif, Sanofi
Lemtrada has beaten Merck Serono’s multiple sclerosis treatment Rebif in a new head-to-head trial, paving the way for regulatory submission …
Sanofi to become world’s biggest drug maker
November 2, 2011Medical Communications, Research and Development, Sales and Marketing Pfizer, Sanofi, top 10
Sanofi will replace Pfizer as the world’s biggest drug maker by revenue next year, according to new forecasts. Pfizer’s nine-year …
David Meeker appointed as chief executive of Genzyme
October 25, 2011Research and Development, Sales and Marketing Genzyme, Sanofi
Sanofi has appointed David Meeker as chief executive of its new biotech acquisition Genzyme. He will report to Christopher Viehbacher, …
Sanofi’s Lemtrada beats Rebif in MS study
October 25, 2011Research and Development, Sales and Marketing Lemtrada, Sanofi
Sanofi’s investigational multiple sclerosis drug Lemtrada has beaten Rebif in a late-stage trial. The Phase III results show that 78% …
Genzyme completes expansion at Waterford plant
October 14, 2011Manufacturing and Production Genzyme, Sanofi
Sanofi’s Genzyme unit has officially opened a €150 million expansion at its ten-year-old biotechnology facility in Waterford, Ireland that will …
Sanofi spots acne vaccine opportunity
September 22, 2011Research and Development Sanofi, acne, dermatology
Sanofi Pasteur has signed a new research deal with the University of California, San Diego for its investigational acne vaccine. …
Sanofi banks on personalised medicine for growth
September 8, 2011Sales and Marketing Genzyme, Sanofi
Sanofi has nailed its colours to the mast of personalised medicine, banking on the purchase of US biotech company Genzyme, …
Sanofi’s Multaq in the dock
September 7, 2011Sales and Marketing Multaq, Sanofi
The EMA will later this month decide whether Sanofi’s Multaq can remain on the market after reports emerged of serious …
Sanofi battles strong headwinds in second quarter
July 29, 2011Sales and Marketing Sanofi
Sanofi’s acquisition of Genzyme helped its revenue grow in the second quarter, but underlying growth from the French firm disappointed. …
Sanofi eyes phase III move for sarilumab in rheumatoid arthritis
July 13, 2011Research and Development Regeneron, Sanofi, ankylosing spondylitis, research and development news, rheumatoid arthritis, sarilumab
Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …
Latest content
Five Facts about cardiovascular disease
